Award to Fund IND-Enabling Activities for the Company's HuCNS-SC(R) Neural Stem Cells in Cervical Spinal Cord Injury
Decision on Funding Alzheimer's Program Deferred to CIRM's September Board Meeting
NEWARK, Calif., July 26, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that the California Institute for Regenerative Medicine (CIRM) has approved an award to the Company and its collaborators for up to $20 million under CIRM's Disease Team Therapy Development Award program (RFA 10-05). The award is to fund preclinical development of StemCells' proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) as a potential treatment for cervical spinal cord injury. The award will provide funding over a maximum four-year period, with the goal of filing an investigational new drug (IND) application to begin clinical testing in that time. CIRM deferred a decision on the Alzheimer's disease application submitted by StemCells and referred the application back to CIRM's Grants Working Group for further consideration. CIRM is expected to review the application again at the next meeting of its governing board currently scheduled for September 6th.
"We understand that this was a very competitive process and we are extremely grateful to CIRM for its support," commented Martin McGlynn, President and CEO of StemCells, Inc. "We view this decision by CIRM as a strong vote of confidence in our neural stem cell technology and the world class team of scientists and clinicians who will be collaborating to translate this exciting research into potential treatments and cures for patients with spinal cord injury. We are currently conducting a Phase I/II trial in thoracic spinal cord injury. This funding now allows us the opportunity to expand testing of our cells for cervical spinal cord injury, the most common form of spinal cord injury."
StemCells will evaluate its HuCNS-SC cells as a potential treatment for cervical spinal cord injury in collaboration with a team led by Aileen Anderson, Ph.D., Associate Professor in the Departments of Physical Medicine and Rehabilitation, and Anatomy and Neurobiology at University of California, Irvine. Dr. Anderson's laboratory has a long history of collaboration with StemCells in spinal cord injury, including the studies which led to the world's first clinical trial for a neural stem cell therapeutic in chronic spinal cord injury. This Phase I/II clinical trial, currently underway in Zurich, Switzerland, recently reported positive safety data from the first cohort of treated patients, and continues to enroll patients from Europe, the United States and Canada.
About Spinal Cord Injury
Spinal cord injury affects approximately 1.3 million people in the United States, for which there are no effective treatment options. Moreover, spinal cord injuries are a significant financial drain on the public health system. Cervical spinal cord injuries represent approximately half of all spinal cord injuries, for which lifetime healthcare costs range from $1.8 to $3.3 million per patient, depending upon severity of the injury.
About CIRM
CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. A list of grants and loans awarded to date may be seen here: http://www.cirm.ca.gov/for-researchers/researchfunding.
The two applications submitted by StemCells, Inc. under CIRM's RFA 10-05 for cervical spinal cord injury and for Alzheimer's disease, as well as the feedback on each application from CIRMS's grants working group, can be viewed on the CIRM website at http://www.cirm.ca.gov/research-summaries-rfa-10-05-cirm-disease-team-therapy-development-awards.
Read the original:
StemCells, Inc. Awarded $20 Million From the California Institute for Regenerative Medicine